文献速递糖尿病甲状腺疾病垂体与肾上腺疾病

酪氨酸激酶抑制剂联合免疫检查点抑制剂的内分泌不良反应

Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于FDA不良事件报告系统的回顾性研究,纳入938464例不良事件报告,其中内分泌不良事件22275例分为TKIs组(n=9181)、ICIs组(n=11363)和TKIs+ICIs组(n=1731)。TKIs+ICIs组内分泌不良事件发生率最高,甲状腺功能减退风险高于ICIs组(OR 1.47,95%CI 1.28-1.69)但低于TKIs组(OR 0.68,95%CI 0.58-0.79);1型糖尿病风险高于TKIs组(OR 26.61,95%CI 18.60-38.07)但低于ICIs组(OR 0.63,95%CI 0.47-0.84);低血糖风险约为ICIs组的2.77倍(OR 2.77,95%CI 1.95-3.95)。联合治疗未增加垂体功能障碍和原发性肾上腺皮质功能不全风险,死亡率与ICIs组相当但显著低于TKIs组。

要点

  • TKIs+ICIs组内分泌不良事件发生率最高,依次高于ICIs组和TKIs组。
  • TKIs+ICIs组甲状腺功能减退风险高于ICIs组但低于TKIs组。
  • TKIs+ICIs组1型糖尿病风险高于TKIs组但低于ICIs组。

核心结论

  • 内分泌不良事件在TKIs+ICIs治疗中更常见,不同腺体在内分泌不良事件分布上联合治疗与单药治疗存在差异。
  • 联合治疗相关内分泌不良事件未增加死亡风险。

研究设计与样本

  • 基于FDA不良事件报告系统的回顾性研究,共识别938464例与3类治疗相关的不良事件报告。
  • 内分泌不良事件共22275例,分为TKIs组(n=9181)、ICIs组(n=11363)和TKIs+ICIs组(n=1731)。

主要发现

  • 内分泌不良事件发生率在TKIs+ICIs组最高,其次为ICIs组和TKIs组。
  • TKIs+ICIs组甲状腺功能减退风险高于ICIs组(OR 1.47,95%CI 1.28-1.69),低于TKIs组(OR 0.68,95%CI 0.58-0.79)。
  • TKIs+ICIs组1型糖尿病风险高于TKIs组(OR 26.61,95%CI 18.60-38.07),低于ICIs组(OR 0.63,95%CI 0.47-0.84)。
  • TKIs+ICIs组低血糖风险约为ICIs组的2.77倍(OR 2.77,95%CI 1.95-3.95),TKIs组低血糖风险也高于ICIs组(OR 3.44,95%CI 2.93-4.03)。
  • 与ICIs组相比,TKIs+ICIs组未显示更高的垂体功能障碍和原发性肾上腺皮质功能不全风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) were recognized to cause endocrine adverse reactions (EARs). However, combination therapy-associated EARs are still unclear. METHODS: This was a retrospective study based on the FDA Adverse Event Reporting System. We identified 938 464 cases of all adverse events related to 3 types of treatments. A total of 22 275 cases were EARs and divided into TKIs (n = 9181), ICIs (n = 11 363), and TKIs + ICIs group (n = 1731). RESULTS: The incidence of EARs was the highest in TKIs + ICIs followed by the ICIs and TKIs group. The TKIs + ICIs group had a higher risk of hypothyroidism than the ICIs group [odds ratio (OR) 1.47, 95% confidence interval (CI) 1.28-1.69] and a lower risk compared to the TKIs group (OR 0.68, 95% CI 0.58-0.79). The TKIs + ICIs group presented a higher risk of type 1 diabetes mellitus compared to the TKIs group (OR 26.61, 95% CI 18.60-38.07) but a lower risk compared to the ICIs group (OR 0.63, 95% CI 0.47-0.84). The risk of hypoglycemia was approximately 2.77 times greater in the TKIs + ICIs group than in the ICIs group (OR 2.77, 95% CI 1.95-3.95) and was also higher in the TKIs group compared to the ICIs group (OR 3.44, 95% CI 2.93-4.03). Compared to the ICIs group, the TKIs + ICIs group did not display a higher risk of pituitary dysfunction and primary adrenal insufficiency. The mortality risk of the TKIs + ICIs group was comparable to the ICIs group but was significantly lower than the TKIs group. CONCLUSION: EARs were more common in TKIs + ICIs therapy. The distribution of EARs in different glands varied among combination therapy and monotherapy. Combination therapy-associated EARs did not increase the risk of mortality.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shao W, Yang K, Lu D, et al. Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors. J Clin Endocrinol Metab. 2025. PMID: 39986331. doi:10.1210/clinem/dgaf117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。